BAY 1135626 is used to synthesize BAY 1129980 for anti-tumor research. BAY 1129980 is an ADC reagent based on Auristatin, which has anti-C4.4A (LYPD3) activity and can be used for research on non-small cell lung cancer (NSCLC). In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) In vitro research C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues.BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines.BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A.BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro. In vivo research BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse.BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment.
Specifictaions: ≥99%
MDL Number: C55H86N10O11
Molecular Formula: 1063.33
- UPC:
- 51442306
- Condition:
- New
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- B767800-1mg
- CAS:
- 1404071-37-9
- Product Size:
- 1mg
